BOSTON, Oct. 26, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company
developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast
slide presentation on Monday, November 6, 2017 at 4:30 p.m. ET to provide a corporate update and discuss financial results for the
third quarter ended September 30, 2017.
The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The
passcode for the conference call is 8769629. To access the slides and live webcast or the subsequent archived recording, visit the
“Investors & Media” section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website
for two weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston-based biotechnology company employing innovative gene expression, control and cell
technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and
graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD
Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use
non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together
with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate,
gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both
clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Contact:
David Connolly
ZIOPHARM Oncology
617-502-1881
dconnolly@ziopharm.com
or
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
